Genus non-exec bulks up stake
A round-up of the biggest director deals today so far.
Professor Barry Furr, a non-executive director at the animal breeding technology group Genus, has spent £30,000 more than doubling his stake in the animal breeding company, the firm confirmed today.
He bought 5,000 shares at 600p a time and now has 8,000.
Furr, a former chief scientist for the drug giant AstraZeneca, bought his initial stake of 3,000 shares at 680p a time in October.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Genus sells breeding technology products to livestock and farmers.
Top Director Buys
Value: £61,350
Value: £30,000
Value: £24,880
Value: £14,880
Top Director Sells
Value: £410,000
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Revolut finally bags a UK banking licence – what next for the fintech?
Revolut has finally been granted a UK banking licence following three years of negotiations with the regulator
By Kalpana Fitzpatrick Published
-
Could Labour impose a “double death tax” of more than 50%?
Speculation is mounting that capital gains tax will be reformed in the Budget - and one option is to charge bereaved families the tax on top of inheritance tax. We explain how it could work
By Ruth Emery Published